z-logo
open-access-imgOpen Access
Synthesis, Characterization of Poly Heterocyclic Compounds, and Effect on Cancer Cell (Hep-2) In vitro.
Author(s) -
Baghdad Science Journal
Publication year - 2018
Publication title -
mağallaẗ baġdād li-l-ʿulūm
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.167
H-Index - 6
eISSN - 2411-7986
pISSN - 2078-8665
DOI - 10.21123/bsj.15.4.415-524
Subject(s) - chemistry , pyridazine , ethyl acetoacetate , hydrazine (antidepressant) , hydrate , amine gas treating , pyridine , pyrrole , yield (engineering) , hydrochloride , proton nmr , organic chemistry , medicinal chemistry , nuclear chemistry , catalysis , materials science , chromatography , metallurgy
A synthesis series of new heterocyclic derivatives (A2-A7) (pyrrole, pyridazine, oxazine and imidazol) derived from 4-acetyl-2,5-dichloro-1-(3,5-dinitrophenyl)-1H-pyrrole-3-carboxylate(A1) have been synthesised. Synthesis of compound (A2) by the reaction of starting material (A1) with hydroxyl amine hydrochloride in the presence of pyridine. Compound (A2) was reacted with hydrazine hydrate in dry benzene to give (A3) derivative. The compound )A3( deals with sodium nitrite to give diazonium salt, and the reaction diazonium salt with ethyl acetoacetate to produce compound (A4). To a mixture of compound (A4) and hydroxyl amine with sttired to yield (A5).Compound (A6) was prepared by reaction compound (A4) with thiosemicarbazide in presence of drops of acetic acid. Synthesis of 1compound (A7) by reaction compound (A6) with ethyl chloro acetate. The reactions have been monitored by TLC and the synthesized compounds were characterized using spectrophotometric methods FT-IR, 1H NMR.The biological effects of the prepared compounds on the cancer cells were studied in vitro. The results indicated that these Synthesized compounds (A1–A7) inhibited1 the cancer1 cells1 efficiently, the compound (A6) was activity inhibited on the cancer cells.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here